JPRN-UMIN000021621尚未招募未知
Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with gastro-esophageal reflux disease (GERD): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an index - Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with gastro-esophageal reflux disease (GERD): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan0 个研究点目标入组 100 人开始时间: 2016年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with a history of gastrointestinal resection or vagotomy (2)Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia),and sudden weight loss (3)Patients with peptic ulcer (except those in scarring stage) (4)Patients with a history of, or who currently have, any of the following diseases Zollinger-Ellison syndrome Inflammatory Bowel Disease (IBD) Irritable Bowel Syndrome (IBS) Esophageal stricture Esophageal achalasia Malabsorption Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction (5)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. (6)Patients with a confirmed, or suspected, malignant lesion (7)Women who are pregnant or who may possibly be pregnant, and lactating mothers (8)Patients who require continued treatment with drugs (atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole, and antacids containing aluminium hydroxide gel and magnesium hydroxide) which may interact with the study drugs (9)Patients receiving treatment with potassium competitive acid blocker, proton pump inhibitors, H2-receptor antagonists, prokinetic agents, gastric mucosa protective agents, anticholinergics, antacids, antidepressants, antianxiety agents, antidiabetic drugs, steroids (excluding external preparations), non-steroid antiinflammatory drugs (NSAIDs), aspirin preparations including low-dose aspirin and/or bisphosphonate drugs. However, patients who discontinue using these drugs for at least 1 week prior to the symptom survey or switch to another treatment, may enrol in the study. (10)Other patients whom the investigator considers unsuitable for admission to the study
研究者
相似试验
尚未招募
不适用
Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an indexpatients with reflux esophagitisJPRN-UMIN000016637Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan100
招募中
3 期
The effect of potassium citrate and double j stent in reducing stone formatiorinary stones.Calculus of kidney with calculus of ureterN20.2IRCT20190624043991N8Tehran University of Medical Sciences70
招募中
3 期
Comparison of the consequences of potassium administration with lower amounts than the estimated amount in hospitalized childreInvestigating the outcome of serum with lower amounts of potassium in children.IRCT20240513061780N1Ghoum University of Medical Sciences114
已完成
不适用
Effectiveness of Potassium Supplement in Hypokalemic PD Patients: A Stratified Randomized Controlled TrialPeritonitisHypokalemia in PD patientPeritonitisHospitalizationCardiovascular mortalityAll-cause mortalityPeritoneal dialysisPotassium supplementHypokalemiaTCTR20190725004Faculty of medicine, Chulalongkorn university192
尚未招募
Unknown
Efficacy of prophylactic potassium-competitive acid blockers after catheter ablation for atrial fibrillatioKCT0009272The Catholic University of Korea, Seoul St. Mary's Hospital60